Avenzo Therapeutics is a biotechnology company developing oncology therapies, including a CDK2 inhibitor for advanced solid tumors and HR+/HER2-negative metastatic breast cancer.

Axonis Therapeutics is a biotechnology company developing novel neuromedicines targeting neurological disorders like epilepsy and pain.

Seaport Therapeutics develops neuropsychiatric medicines using its Glyph technology platform to enhance oral bioavailability and reduce side effects, with a focus on treating depression, anxiety, and other disorders.

Aiolos Bio is a clinical-stage biopharmaceutical company focused on respiratory and inflammatory conditions, with a lead drug candidate, AIO-001, that is a potentially best-in-class TSLP antibody dosed every 6 months.

Star Therapeutics is a biotechnology company that develops first-in-class antibody therapies, primarily for hematology and immunology, and also generates additional biotech companies focused on discovering and advancing novel antibody therapies.

Rapport Therapeutics is a clinical-stage biotechnology company that develops precision neuromedicines for seizure and psychiatric disorders by targeting specific neuroanatomical regions, aiming to provide better alternatives to current treatments by reducing unwanted drug-target interactions.